Subscribe to Finance

The Lead

Dyadic International Q1 Results

May 15, 2015 11:59 am | by Dyadic International | News | Comments

Dyadic International, Inc. is a global biotechnology company focused on enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries.

Puma Biotech Stumbles With Breast Cancer Drug

May 15, 2015 11:53 am | by The Associated Press | News | Comments

Treatment results with the breast cancer drug Herceptin, as well as chemotherapy, did improve,...

TRACON Q1 Results

May 14, 2015 11:29 am | by TRACON Pharmaceuticals | News | Comments

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company, today announced its...

Obamacare Ruling Could Impact States, But Not Lawmakers

May 13, 2015 11:26 am | by Ricardo Alonso-Zaldivar, Associated Press | News | Comments

If the Supreme Court rules the way most Republicans want in the latest health overhaul case, GOP...

View Sample

FREE Email Newsletter

Vitae Pharmaceuticals Q1 Results

May 13, 2015 11:19 am | by Vitae Pharmaceuticals | News | Comments

Vitae Pharmaceuticals, a clinical-stage biotechnology company, recently provided financial results and pipeline reports for the first quarter of 2015.

Fibromyalgia Treatment Market Slowing

May 13, 2015 11:08 am | by GlobalData | News | Comments

The treatment market value for fibromyalgia across the seven major markets will reach $1.9 billion by 2023, according to research and consulting firm GlobalData.

Novavax Announces Q1 Results

May 8, 2015 10:58 am | by Novavax | News | Comments

Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Q1 results.


Portola Pharmaceuticals Q1 Results

May 7, 2015 11:35 am | by Portola Pharmaceuticals | News | Comments

Portola Pharmaceuticals today provided a corporate update and reported its financial results for the first quarter.

Alzheimer Treatments Worth $13B by 2023

May 6, 2015 10:53 am | News | Comments

The global market for Alzheimer’s Disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023.

Amyris Unveils Q1 Results

May 6, 2015 10:47 am | by Amyris | News | Comments

Amyris, Inc., the industrial bioscience company, today announced financial results for the first quarter of 2015.

Sagent Unveils Q1 Results

May 5, 2015 11:50 am | by Sagent Pharmaceuticals | News | Comments

Sagent Pharmaceuticals, Inc., a maker of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the first quarter.

AMAG Pharmaceuticals Q1 Results

May 5, 2015 11:39 am | by AMAG Pharmaceuticals | News | Comments

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, today reported unaudited consolidated financial results for the first quarter of 2015.


Capital Investments: Regulations, Technology and ROI

May 5, 2015 10:45 am | by Jeff Reinke, Editorial director | Blogs | Comments

Pharmaceutical processors face a number of challenges in determining the direction they should take when considering internal investments – but a lack of options have never been amongst them.

Rural Hospitals Struggle to Stay Open, Adapt to Changes

May 4, 2015 11:27 am | by David A. Lieb, Associated Press | News | Comments

Sac-Osage is one of a growing number of rural U.S. hospitals closing their doors, citing a complex combination of factors that have put more financial pressure on facilities.

Medicare Contrast in Generic, Brand Prescribing

May 4, 2015 11:21 am | by Lauran Neergaard, AP Medical Writer | News | Comments

The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium.

TESARO Announces Q1 Operating Results

May 1, 2015 10:53 am | by TESARO | News | Comments

TESARO, Inc., an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.

Prostate Cancer Treatment Market To Grow To $8.2 Billion

April 30, 2015 11:46 am | News | Comments

The global treatment market value for prostate cancer will expand more than threefold by 2023.


Flexion Therapeutics Awarded DoD Grant

April 30, 2015 11:38 am | by Flexion Therapeutics | News | Comments

Flexion Therapeutics announced a DoD grant for a clinical trial investigating FX006 as treatment for osteoarthritis ("OA") pain in military personnel.

Epigenomics Receives $3.1 Million Grant

April 29, 2015 11:15 am | by Epigenomics AG | News | Comments

Epigenomics AG today announced that the Company will receive an EU grant under the industrial leadership Horizon 2020 research and innovation program. 

Mylan Raises Offer To Acquire Perrigo

April 29, 2015 11:08 am | by Mylan | News | Comments

Mylan N.V. today announced that it has increased its offer to acquire the issued and to be issued shares of Perrigo.

AstraZeneca Profit Falls as Patent Expires on Heartburn Drug

April 24, 2015 10:43 am | by The Associated Press | News | Comments

Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales.

Aerie Pharma Plunges Aftermarket as Rhopressa Study Fails

April 24, 2015 10:35 am | by The Associated Press | News | Comments

Shares of Aerie Pharmaceuticals lost two-thirds of their value in after-market trading after the company said its experimental eye pressure drug Rhopressa failed in a late-stage clinical trial.

Divestment Gains Boost Net Earnings at Novartis

April 23, 2015 4:48 pm | by The Associated Press | News | Comments

Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies.

Roche Reports Strong Sales Growth in The First Quarter of 2015

April 22, 2015 11:17 am | by Roche | News | Comments

The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in pharmaceuticals, and immunodiagnostics products driving growth in diagnostics.

Fed Grant for Pain-Free Blood Test Startup at UW

April 17, 2015 12:32 pm | by University of Wisconsin - Madison | News | Comments

A company with deep roots at the University of Wisconsin-Madison wants to make blood sampling less painful and more convenient.

Innocrin Raises $28 Million in Series D Financing

April 15, 2015 11:10 am | by Innocrin Pharmaceuticals | News | Comments

Innocrin Pharmaceuticals is developing small-molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers.

Recipharm Equity Investment in Synthonics

April 14, 2015 11:43 am | by Recipharm | News | Comments

$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.

Top Mid-Cap Biotech Companies Increased Revenues to $26.5 Billion in 2014

April 9, 2015 2:10 pm | by GlobalData | News | Comments

GlobalData’s Healthcare Industry Analyst says the rise in biotech peer group total revenue over the past year was driven by Regeneron and Alexion, both of which posted sales of more than $2 billion in 2014.

World Health Day: Budget Cuts, Vaccine Fears Threaten Health Progress

April 7, 2015 1:11 pm | by Alice Hazelton, SciDev.Net | News | Comments

Cuts to global health research budgets and people’s wariness of vaccines could hamper efforts to improve health around the world.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.